censes to, 402 issued U.S. patents and 383 pending U.S. patent applications, including 22 allowed applications that have not yet issued as patents. Its issued patents have terms that expire between 2014 and 2032. Research and Development The company’s research and development expenses were $276.7 million for the year ended December 29, 2013. Significant Events In August 2014, Illumina, Inc. announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system. In August 2014, AstraZeneca has entered into a collaboration with Illumina Inc. to develop its next generation sequencing, or NGS, platform for companion diagnostic tests applicable across AstraZeneca's oncology portfolio. In October 2014, Reprogenetics Inc. announced that the company has signed a collaboration agreement with Illumina as its preferred partner for the research and development of in-vitro fertilization (IVF)-related sequencing technologies. In November 2014, bioMérieux and Illumina announced that they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. History Illumina, Inc. was founded in 1998. The company was incorporated in California in 1998 and reincorporated in Delaware in 2000.
(ILMN:Consolidated Issue Listed on NASDAQ Global Select )
5200 Illumina Way
San Diego, CA 92122
|Avago Technologies Ltd||$106.73 USD||-0.25|
|Becton Dickinson and Co||$143.49 USD||+0.09|
|Dr Reddy's Laboratories Ltd||3,212 INR||-137.20|
|Sigma-Aldrich Corp||$137.49 USD||-0.20|
|Waters Corp||$116.11 USD||+1.66|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.